Immunocore Holdings plc IMCR
NasdaqGS
$27.82-1.22 (-4.20%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
AI giants are pouring hundreds of billions into new health focused tools, and hospitals, insurers and drug makers are under pressure to show they can use that firepower to cut costs and ease staffing strains. That puts high quality healthcare stocks with strong balance sheets and solid execution in a sweet spot. This article highlights three of the strongest options from our curated healthcare shortlist. The three healthcare stocks profiled below are just a small sample, and the full screen...
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma Topline overall survival data expected as early as end of 2026 (OXFORDSHIRE, England & CONSHOHOCKEN, PA & ROCKVILLE, MD, US, 14 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.
IMCR is in the latest 13F portfolio of 1 of the gurus we follow.
